"Commercialization Readiness from Preclinical to 1st Launch: The First Time CEOs Playbook"will equip early-stage biotechnology leaders with the commercialization knowledge they need to strategically position their organizations for financing success and meet critical Commercial and Medical Affairs milestones.

The drug development process is complex and multifaceted, and understanding the commercialization considerations at each phase is vital. From preclinical to first product launch, this one-day course will help biotech executives make informed strategic choices for long-term success. "This course will equip early-stage biotechnology leaders with the commercialization knowledge they need to strategically position their organizations for financing success and meet critical Commercial and Medical Affairs milestones.

Beginning with Phase I, this interactive course will cover the phase-specific commercialization activities and preparation emerging companies need to make for a successful first launch, including Market analysis with competitive landscape assessment, the Commercialization Roadmap development including launch critical success factors, FTEs and dollar spend required for launch, market access pricing and reimbursement, value proposition development, and go-to-market preparation and regulatory considerations. Note that these early commercial flows inform emerging biotech companies' corporate and partnering strategies.

Russ Belden, founder and CEO of Bridge, will guide you through this course by sharing real-world examples and valuable insights. Russ is a biotech commercialization leader with over 36 years of senior operational experience in the preclinical to 1st launch space and a popular Biotech Primer instructor.

• Identify financing success and critical commercial and medical affairs milestones.
• Discover strategic positioning to make informed strategic choices for long-term success, from preclinical stages to the first product launch.
• Gain a comprehensive understanding of phase-specific activities, such as market analysis, value proposition development, pricing, reimbursement, and regulatory considerations.
• Explain how early commercial flows will inform emerging biotech companies’ corporate and partnering strategies.
• Discover key elements that influence successful commercial launches, including target product profiles, revenue forecasting, market research, key hires, branding, and life cycle management.

Course Price:
BIO Member: $1,450
Non-Member: $1,820